The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 920: 4. Changes made in revising the Model List: 4.4 Other changes: 4.4.2 Streptokinase

The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 920
(2003; 137 pages)

Índice de contenido

1. Introduction
2. Open session
3. Update on current activities
	3.1 Dissemination of the previous report of the Expert Committee (including the 12th Model List)
	3.2 The twenty-fifth anniversary of the WHO Model List of Essential Medicines
	3.3 The WHO model formulary
	3.4 Review of the New Emergency Health Kit
	3.5 Review of essential medicines for reproductive health
	3.6 Report of an ad hoc Advisory Committee on priority vaccines
	3.7 The WHO Essential Medicines Library
	3.8 Promoting rational use of essential medicines
		3.8.1 Update on activities to contain antimicrobial resistance
		3.8.2 Guidelines for drugs and therapeutic committees
		3.8.3 WHO database on rational drug use studies
4. Changes made in revising the Model List
	4.1 Applications for additions
		4.1.1 Amodiaquine
		4.1.2 Azithromycin
		4.1.3 Ibuprofen (paediatric formulation)
		4.1.4 Insulin semilente
		4.1.5 Miconazole nitrate buccal tablets
		4.1.6 Misoprostol
		4.1.7 Valaciclovir
	4.2 Applications for deletions
		4.2.1 Ethinylestradiol + levonorgestrel tablets (50µg + 250µg, pack of four)
		4.2.2 Nonoxynol
	4.3 Applications for addition of information
		4.3.1 Anti-leprosy medicines
	4.4 Other changes
		4.4.1 Oral rehydration salts
		4.4.2 Streptokinase
5. Reviews of sections of the Model List
	5.1 "Fast-track" procedure for deleting items from the Model List
	5.2 Review of core versus complementary listing of medicines
	5.3 Review of the use of the square box symbol (including a review of the corticosteroids)
	5.4 Review of the antihypertensive medicines
6. Priorities for future reviews
7. Recommendations
	7.1 Additions, deletions and other changes to the Model List
	7.2 Core versus complementary listing of medicines
	7.3 Use of the square box symbol (including review of the corticosteroids
	7.4 Review of the antihypertensive medicines
	7.5 Future priorities
References
Annex 1 The 13th WHO Model List of Essential Medicines
Annex 2 The Anatomical Therapeutic Chemical (ATC) classification system¹
Alphabetical list of essential medicines (with ATC classification code numbers)
Selected WHO Publications of Related Interest

4.4.2 Streptokinase

The Committee reviewed an application submitted by Aventis Behring, GmbH, Marburg Germany, to remove the 100000IU dosage form of streptokinase from the Model List¹ (section 12.5 Antithrombotic medicines).

¹ Details of the full application (including comments received) are available via the Internet from the WHO web site (http://www.who.int/medicines).

The Committee noted that the recommended standard dosage for streptokinase's main indication, the treatment of acute myocardial infarction, is 1.5 million IU. The Committee recommended that the dosage form for streptokinase be changed to: powder for injection, 1.5 million IU in vial and that the note, "For use in rare or exceptional circumstances." be removed since its value in treating acute myocar-dial infarction is now well established and its use is no longer reserved for exceptional situations.